Retatrutide dosage

Retatrutide injectable dosage

Documented investigational weekly doses are 1, 4, 8 and 12 mg, with lower starting amounts for the higher-dose schedules and a 48-week treatment period. These are distinct assigned dose levels, rather than instructions to increase automatically from 1 to 12 mg. Another reported weekly pattern starts at 2 mg for four weeks, uses 4 mg for the next four weeks, then 4–8 mg from week 9, for 24 weeks or longer. This is a separate reported progression, not a replacement for a specific investigational protocol.[1][17]

Retatrutide acts at GIP, GLP-1 and glucagon receptors. Its intended metabolic effects concern appetite, energy expenditure and body weight; it has no approved prescribing regimen.[1][2][3][4][5][6][7]

Frequency and timing

Use the same injection day each week.[1][3][4]

Cycle length and breaks

Injectable: 48 weeks (phase 2). A standard break interval between courses is not established.[1]

Approval and product quality

Retatrutide is not an FDA-approved drug.[5][8]

Side effects and long-term safety

Nausea, vomiting, diarrhea and other gastrointestinal effects are relevant. Rare adverse effects, long-term safety, effects after discontinuation and safety in special populations remain uncertain. Retatrutide remains investigational.[1][12][16][7][8][9]

Route-specific dosing limits

The main cautions are unapproved-product toxicity alerts, import or supply risk, and unreviewed combinations with other incretin or weight-loss drugs. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[9][15][1][7][17]